Hydralazine Hydrochloride
PrescriptionHandelsnamen: Hydralazine Hydrochloride
About This Medication
DESCRIPTION HydrALAZINE hydrochloride, USP, is an antihypertensive, for oral administration. Its chemical name is 1-hydrazinophthalazine monohydrochloride, and its structural formula is: HydrALAZINE hydrochloride, USP is a white to off-white, odorless crystalline powder. It is soluble in water, slightly soluble in alcohol, and very slightly soluble in ether. It melts at about 275°C, with decomposition. Each tablet for oral administration contains 25 mg hydrALAZINE hydrochloride, USP. Tablets also contain magnesium stearate, microcrystalline cellulose, orange lake blend, silicon dioxide, and sodium starch glycolate. The orange lake blend consists of FD&C yellow #6. chemical-structure
Wirkstoffe
| Wirkstoff | Stärke |
|---|---|
| Hydralazine Hydrochloride | - |
Indikationen und Anwendung
Dosierung und Verabreichung
Side Effects Overview
Warnhinweise und Vorsichtsmaßnahmen
WARNINGS In a few patients hydrALAZINE may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis. In such patients hydrALAZINE should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug. Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later. Long-term treatment with steroids may be necessary. (See PRECAUTIONS, Laboratory Tests .)
Kontraindikationen
CONTRAINDICATIONS Hypersensitivity to hydrALAZINE; coronary artery disease; mitral valvular rheumatic heart disease.
Frequently Asked Questions
INDICATIONS AND USAGE Essential hypertension, alone or as an adjunct.
DOSAGE AND ADMINISTRATION Initiate therapy in gradually increasing dosages; adjust according to individual response. Start with 10 mg four times daily for the first 2 to 4 days, increase to 25 mg four times daily for the balance of the first week. For the second and subsequent weeks, increase dosage to 50 mg four times daily. For maintenance, adjust dosage to the lowest effective levels. The incidence of toxic reactions, particularly the L.E. cell syndrome, is high in the group …
WARNINGS In a few patients hydrALAZINE may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis. In such patients hydrALAZINE should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug. Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later. Long-term treatment with steroids may be necessary. (See PRECAUTIONS, Laboratory Tests .)
CONTRAINDICATIONS Hypersensitivity to hydrALAZINE; coronary artery disease; mitral valvular rheumatic heart disease.
Hydralazine Hydrochloride is a prescription medication. You will need a valid prescription from a licensed healthcare provider.
Similar Tablet Products
Browse all Tablet products →References & Data Sources
- • DailyMed — Hydralazine Hydrochloride drug label (National Library of Medicine)
- • openFDA — Hydralazine Hydrochloride label data (U.S. Food & Drug Administration)
- • RxNorm — RXCUI 905225 (NLM Normalized Drug Names)
- • NDC Directory — Hydralazine Hydrochloride (FDA National Drug Code)
Medizinischer Haftungsausschluss
Die Informationen auf dieser Seite dienen ausschließlich zu Bildungszwecken und sollten nicht als Ersatz für professionellen ärztlichen Rat, Diagnose oder Behandlung verwendet werden.
Wenden Sie sich bei Fragen zu einem medizinischen Zustand oder einem Arzneimittel stets an Ihren Arzt oder einen anderen qualifizierten Angehörigen der Gesundheitsberufe.
Datenquellen: DailyMed (NLM), openFDA, MFDS